Is the Apogee deal important for AbbVie?

Yes, the acquisition aims to strengthen AbbVie's immunology pipeline, potentially supporting future growth.

What challenges does AbbVie face?

Challenges include competition in the immunology market, regulatory pressures, and reliance on a few key drugs.

Does AbbVie pay dividends?

Yes, AbbVie is known for its attractive dividend yield, making it popular among income investors.

AbbVie Stock Analysis: Can Skyrizi, Rinvoq Sustain 9% YTD Rally?

AbbVie (ABBV) stock has rallied 9% year-to-date, driven by Skyrizi and Rinvoq growth offsetting Humira's decline. The key question is whether its pipeline and Apogee acquisition can sustain long-term momentum.

July 15, 2026

2 min read

Source: Zacks

Key Numbers

ytd return

AbbVie (ABBV) stock has risen 9% year-to-date in 2026, supported by strong sales of Skyrizi and Rinvoq, which are compensating for declining Humira revenues. However, the sustainability of this momentum depends on the company's pipeline and the Apogee deal.

Rating Change

No specific rating change is mentioned in the original article, but the analysis highlights the positive performance driven by new drugs.

Analyst Rationale

Analysts point to Skyrizi and Rinvoq as the key growth drivers post-Humira patent expiry. The Apogee acquisition aims to bolster the immunology pipeline.

Context

ABBV shares are trading near their 52-week highs. The healthcare sector faces regulatory and competitive pressures, but AbbVie maintains an attractive dividend yield.

What to Make of It

AbbVie appears to be successfully transitioning from Humira to newer drugs, but investors should monitor pipeline developments and competition in the immunology space.

Frequently Asked Questions

The rally is driven by strong sales of Skyrizi and Rinvoq, offsetting the decline in Humira revenues.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.